CytoTools AG
XETRA:T5O
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
CytoTools AG
Total Current Assets
CytoTools AG
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CytoTools AG
XETRA:T5O
|
Total Current Assets
€1.2m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-7%
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Total Current Assets
€19.5B
|
CAGR 3-Years
127%
|
CAGR 5-Years
113%
|
CAGR 10-Years
N/A
|
|
|
MorphoSys AG
XETRA:MOR
|
Total Current Assets
€675m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
13%
|
CAGR 10-Years
6%
|
|
|
Immatics NV
NASDAQ:IMTX
|
Total Current Assets
€449.4m
|
CAGR 3-Years
23%
|
CAGR 5-Years
227%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Total Current Assets
€704.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Formycon AG
XETRA:FYB
|
Total Current Assets
€67.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
CytoTools AG
Glance View
CytoTools AG is a biotechnology company, which engages in the research and development of therapies to treat cause of diseases. The company is headquartered in Darmstadt, Hessen and currently employs 1 full-time employees. The company went IPO on 2007-05-18. The firm holds interests in research and development (R&D) companies DermaTools Biotech GmbH, which is active in the field of dermatology and urology, and CytoPharma GmbH, which is engaged in product development for cardiovascular diseases, cancer and other indications. CytoTools AG manages the patent portfolio and coordinates the licensing for its subsidiaries. The product pipeline of disease modifying therapies based on the mechanisms of cell growth and programmed cell death, comprising small molecules and biologics across a range of disease indications, includes DermaPro, the Company's lead product indicated for diabetic and venous foot ulcers in phase III of clinical trials, as well as Utisept, an urological medical device for flushing the bladder in urinary tract infections, and pre-clinical stage CardioClean for the treatment of restenosis, diabetis and carotis-stenosis.
See Also
What is CytoTools AG's Total Current Assets?
Total Current Assets
1.2m
EUR
Based on the financial report for Jun 30, 2023, CytoTools AG's Total Current Assets amounts to 1.2m EUR.
What is CytoTools AG's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
-7%
Over the last year, the Total Current Assets growth was -72%. The average annual Total Current Assets growth rates for CytoTools AG have been -9% over the past three years , -13% over the past five years , and -7% over the past ten years .
You don't have any saved screeners yet
